The application relates to a lipid conjugate of formula M-X1-L wherein M is a molecule of interest such as a drug moiety; X1 is a linker group such as ester, ether or carbamate; and L is a lipid scaffold represented by formula (IId): -L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6 and wherein L comprises 5 to 40 carbon atoms and 0 to 2 carbon-carbon double bonds. The lipid conjugate can p be formulated in a drug delivery vehicle such as a lipid nanoparticle (LNP).

The present disclosure relates to molecularly imprinted polymers that target cannabinoid(s), including THC and CBD, as well as methods of making molecularly imprinted polymers that target cannabinoid(s), including THC and CBD and uses thereof.

The present disclosure relates to molecularly imprinted polymers that target cannabinoid(s), including THC and CBD, as well as methods of making molecularly imprinted polymers that target cannabinoid(s), including THC and CBD and uses thereof.

Provided are an environmentally-friendly high-efficiency method of manufacturing an ester compound based on an esterification reaction using a salt ion-exchange method and an ester compound manufactured thereby. In the conventional esterification reaction, an ester was produced in low yields due to the hydrolysis (i.e., reverse reaction) caused by water, or it was required to continuously supply hydrochloric acid gas or use thionyl chloride, which is a hazardous material, and thus there were limitations in terms of environmental friendliness or cost. On the other hand, in the present invention, hydrochloric acid gas is continuously supplied using the salt ion-exchange method, and since magnesium sulfate acts as a dehydrating agent, the water generated in the esterification reaction is removed, and thus the occurrence of hydrolysis (i.e., reverse reaction) is suppressed and a conversion rate to the desired ester compound is increased. In addition, since the reactants are inexpensive and the product is less hazardous and easy to handle, a more efficient reaction is possible.

Provided are an environmentally-friendly high-efficiency method of manufacturing an ester compound based on an esterification reaction using a salt ion-exchange method and an ester compound manufactured thereby. In the conventional esterification reaction, an ester was produced in low yields due to the hydrolysis (i.e., reverse reaction) caused by water, or it was required to continuously supply hydrochloric acid gas or use thionyl chloride, which is a hazardous material, and thus there were limitations in terms of environmental friendliness or cost. On the other hand, in the present invention, hydrochloric acid gas is continuously supplied using the salt ion-exchange method, and since magnesium sulfate acts as a dehydrating agent, the water generated in the esterification reaction is removed, and thus the occurrence of hydrolysis (i.e., reverse reaction) is suppressed and a conversion rate to the desired ester compound is increased. In addition, since the reactants are inexpensive and the product is less hazardous and easy to handle, a more efficient reaction is possible.

Synthetic kava analog compounds of formula I are disclosed. Specifically, kava analogs of the structural type 3-oxoclclohex-1-en-1-yl benzoates, and corresponding benzamides are disclosed. The compounds of the within invention are useful in the inhibition of cytokine TNF-α, the management of chronic inflammation such as but not limited to Porphyromonas gingivalis induced periodontitis, and in infective arthritis, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other anti-inflammatory active pharmaceutical ingredients. Methods of treating chronic inflammation such as periodontitis and infective arthritis are also disclosed.

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

Provided are stellate compounds that target spike proteins and have a significant anti-SARS-CoV-2 ability and a certain broad spectrum. Such molecules and salts thereof have at least one basic unit R(X).sub.n, which binds at an orthotopic binding site such as an MD domain or an allosteric site, to a virus containing spike proteins or a virus having spike proteins on its surface, thereby preventing coronavirus or other viruses which express spike proteins on their surfaces from invading host cells, and preventing the occurrence of viral infection. In addition, interaction of the molecules and salts thereof with vitamin K-dependent proteins in the human body inhibits the expression of vitamin K so as to inhibit blood coagulation in the human body, thereby treating thrombosis caused by coronavirus and producing a curative effect for pneumonia caused by a severe viral infection.

Provided are stellate compounds that target spike proteins and have a significant anti-SARS-CoV-2 ability and a certain broad spectrum. Such molecules and salts thereof have at least one basic unit R(X).sub.n, which binds at an orthotopic binding site such as an MD domain or an allosteric site, to a virus containing spike proteins or a virus having spike proteins on its surface, thereby preventing coronavirus or other viruses which express spike proteins on their surfaces from invading host cells, and preventing the occurrence of viral infection. In addition, interaction of the molecules and salts thereof with vitamin K-dependent proteins in the human body inhibits the expression of vitamin K so as to inhibit blood coagulation in the human body, thereby treating thrombosis caused by coronavirus and producing a curative effect for pneumonia caused by a severe viral infection.

Disclosed are compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions.